FMC-376 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This FMC-376 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether FMC-376 can convert its Small molecule drug profile and KRAS G12C biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | FMC-376 (query alias: FMC-376) |
|---|---|
| Modality / target | Small molecule drug; KRAS G12C; KRAS G12C inhibitors |
| Highest global status | Phase 1/2 |
| Originator | Frontier Medicines Corp. |
| Active developers | Frontier Medicines Corp. |
The MCP disease footprint includes KRAS G12C mutant Colorectal Cancer, KRAS G12C mutation Solid Tumors, Metastatic Solid Tumor. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06244771 | Phase 1/2 | Recruiting | 403 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Evidence gap
The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
FMC-376 addresses KRAS G12C mutant Colorectal Cancer, KRAS G12C mutation Solid Tumors, Metastatic Solid Tumor. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 25 matched transaction record(s) under the scope “target-level comparable: KRAS G12C.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: KRAS G12C records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-08-10 | Revolution Medicines granted BeOne exclusive rights in select Asian markets to develop and commercialize or solely commercialize, depending on the market, four clinical-stage RAS(ON) inhibitors. | Phase 3 | Financial terms not disclosed |
| 2026-08-04 | Amplia signs Collaboration and Supply Agreement with Lilly | Phase 2 | Financial terms not disclosed |
| 2025-08-25 | Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Method for treating autophagy dependent cancer with a pikfyve inhibitor”. The milestone feed surfaced a patent-application signal described as “Ribonucleotide reductase (RNR) compositions and methods of use”. The milestone feed surfaced a patent-application signal described as “Farnesyltransferase inhibitors for treatment of KRAS-dependent cancers”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
